Dr. Nguyen on Future Research in High-Risk Prostate Cancer


Paul L. Nguyen, MD, discusses future research in high-risk prostate cancer.

Paul L. Nguyen, MD, senior physician and director of Genitourinary Clinical Center for Radiation Oncology at Dana-Farber Cancer Institute, and a professor of radiation oncology at Harvard Medical School, discusses future research in high-risk prostate cancer.

Future research efforts in high-risk prostate cancer should focus on personalizing therapy ​for patients, says Nguyen. For example, ​a one-size-fits-all approach is currently utilized with androgen deprivation therapy.

As such, the field is anticipating results from the phase 3 Predict-RT trial​, which will use genomics to assist in the personalization of therapy for patients​, explains Nguyen.

Additionally, future research efforts are focused on minimizing the adverse effects associated with hormone therapy by using genomic markers to inform deintensification strategies. Both emerging approaches continue to garner significant excitement in the space, Nguyen concludes.

Related Videos
Ariel Grajales-Cruz, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic